Prostate-specific membrane androgen PET/CT can help clinicians intensify or de-escalate care for men with prostate cancer who have biochemical recurrence following radical prostatectomy.A ...

The effects of the extent of lymph node dissection during radical prostatectomy on prostate cancer survival outcomes have been unclear, pending long-term follow-up data from randomized controlled ...

Top experts share the latest bladder, kidney and prostate cancer advances from the 2026 ASCO GU Symposium, highlighting patient impact. At the 2026 ASCO GU meeting, experts gathered to share the ...

A new cohort study included 778 men with prostate cancer who had received either radiation or surgery within 1 year of diagnosis. Patients who lived in rural areas had nearly twice the rate of ...

Short-course (3-month) enzalutamide monotherapy in biochemically recurrent prostate cancer (BCR): Preliminary prostate specific membrane antigen tumor volume (PSMA-TV) data. Anatomical location of ...

ROCHESTER, Minn. — To help meet the potentially complex needs of patients after prostate cancer treatment and offer the precision and care necessary in the follow-up journey, Mayo Clinic’s Department ...

Rural men had almost twice the risk of prostate cancer biochemical recurrence as urban men in the US. Patients living in rural areas may be at an increased risk for prostate cancer biochemical ...

(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a plenary prostate cancer session and a ...

XTANDI: the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical ...

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.